BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 38279870)

  • 1. Combining TIGIT blockade with IL-15 stimulation is a promising immunotherapy strategy for lung adenocarcinoma.
    Luo B; Sun Y; Zhan Q; Luo Y; Chen Y; Fu T; Yang T; Ren L; Xie Z; Situ X; Liu B; Tang K; Ke Z
    Clin Transl Med; 2024 Jan; 14(1):e1553. PubMed ID: 38279870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TIGIT and PD1 Co-blockade Restores ex vivo Functions of Human Tumor-Infiltrating CD8
    Ge Z; Zhou G; Campos Carrascosa L; Gausvik E; Boor PPC; Noordam L; Doukas M; Polak WG; Terkivatan T; Pan Q; Takkenberg RB; Verheij J; Erdmann JI; IJzermans JNM; Peppelenbosch MP; Kraan J; Kwekkeboom J; Sprengers D
    Cell Mol Gastroenterol Hepatol; 2021; 12(2):443-464. PubMed ID: 33781741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting CD96 overcomes PD-1 blockade resistance by enhancing CD8+ TIL function in cervical cancer.
    Wang Y; Wang C; Qiu J; Qu X; Peng J; Lu C; Zhang M; Zhang M; Qi X; Li G; Hua K
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35288463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TIGIT Blockade Exerts Synergistic Effects on Microwave Ablation Against Cancer.
    Chen Y; Huang H; Li Y; Xiao W; Liu Y; Chen R; Zhu Y; Zheng X; Wu C; Chen L
    Front Immunol; 2022; 13():832230. PubMed ID: 35320940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-1 and TIGIT coexpressing CD8 + CD103 + tissue-resident memory cells in endometrial cancer as potential targets for immunotherapy.
    Jiang F; Mao M; Jiang S; Jiao Y; Cao D; Xiang Y
    Int Immunopharmacol; 2024 Jan; 127():111381. PubMed ID: 38150880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8
    Banta KL; Xu X; Chitre AS; Au-Yeung A; Takahashi C; O'Gorman WE; Wu TD; Mittman S; Cubas R; Comps-Agrar L; Fulzele A; Bennett EJ; Grogan JL; Hui E; Chiang EY; Mellman I
    Immunity; 2022 Mar; 55(3):512-526.e9. PubMed ID: 35263569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling.
    Josefsson SE; Huse K; Kolstad A; Beiske K; Pende D; Steen CB; Inderberg EM; Lingjærde OC; Østenstad B; Smeland EB; Levy R; Irish JM; Myklebust JH
    Clin Cancer Res; 2018 Feb; 24(4):870-881. PubMed ID: 29217528
    [No Abstract]   [Full Text] [Related]  

  • 8. IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma.
    Chauvin JM; Ka M; Pagliano O; Menna C; Ding Q; DeBlasio R; Sanders C; Hou J; Li XY; Ferrone S; Davar D; Kirkwood JM; Johnston RJ; Korman AJ; Smyth MJ; Zarour HM
    Clin Cancer Res; 2020 Oct; 26(20):5520-5533. PubMed ID: 32591463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ectopic Expression of TIGIT in Lung Adenocarcinoma and Its Clinical Significance.
    He S; Qian N; Ren S; Ma C; Shen D; Tian Y
    Crit Rev Eukaryot Gene Expr; 2024; 34(3):27-36. PubMed ID: 38305286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TOX-expressing terminally exhausted tumor-infiltrating CD8
    Han HS; Jeong S; Kim H; Kim HD; Kim AR; Kwon M; Park SH; Woo CG; Kim HK; Lee KH; Seo SP; Kang HW; Kim WT; Kim WJ; Yun SJ; Shin EC
    Cancer Lett; 2021 Feb; 499():137-147. PubMed ID: 33249194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD226 identifies functional CD8
    Huang H; Huang Z; Ge J; Yang J; Chen J; Xu B; Wu S; Zheng X; Chen L; Zhang X; Jiang J
    Front Immunol; 2023; 14():1150803. PubMed ID: 37056782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TIGIT Can Exert Immunosuppressive Effects on CD8+ T Cells by the CD155/TIGIT Signaling Pathway for Hepatocellular Carcinoma In Vitro.
    Zhang C; Wang Y; Xun X; Wang S; Xiang X; Hu S; Cheng Q; Guo J; Li Z; Zhu J
    J Immunother; 2020 Oct; 43(8):236-243. PubMed ID: 32804915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose anti-VEGFR2 therapy promotes anti-tumor immunity in lung adenocarcinoma by down-regulating the expression of layilin on tumor-infiltrating CD8
    Yang B; Deng B; Jiao XD; Qin BD; Lu Y; Zhang W; Guo Y; Chen S; Li D; Li B; Zang YS
    Cell Oncol (Dordr); 2022 Dec; 45(6):1297-1309. PubMed ID: 36260222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined evaluation of the expression status of CD155 and TIGIT plays an important role in the prognosis of LUAD (lung adenocarcinoma).
    Sun Y; Luo J; Chen Y; Cui J; Lei Y; Cui Y; Jiang N; Jiang W; Chen L; Chen Y; Kuang Y; Tang K; Ke Z
    Int Immunopharmacol; 2020 Mar; 80():106198. PubMed ID: 31954274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment.
    Kawashima S; Inozume T; Kawazu M; Ueno T; Nagasaki J; Tanji E; Honobe A; Ohnuma T; Kawamura T; Umeda Y; Nakamura Y; Kawasaki T; Kiniwa Y; Yamasaki O; Fukushima S; Ikehara Y; Mano H; Suzuki Y; Nishikawa H; Matsue H; Togashi Y
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34795004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.
    Chauvin JM; Pagliano O; Fourcade J; Sun Z; Wang H; Sander C; Kirkwood JM; Chen TH; Maurer M; Korman AJ; Zarour HM
    J Clin Invest; 2015 May; 125(5):2046-58. PubMed ID: 25866972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD226
    Jin HS; Ko M; Choi DS; Kim JH; Lee DH; Kang SH; Kim I; Lee HJ; Choi EK; Kim KP; Yoo C; Park Y
    Cancer Immunol Res; 2020 Jul; 8(7):912-925. PubMed ID: 32265229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LAG3 and TIGIT Expression on Tumor-Infiltrating Lymphocytes in Cutaneous Melanoma.
    Naimy S; Bzorek M; Eriksen JO; Løvendorf MB; Litman T; Dyring-Andersen B; Gjerdrum LMR
    Dermatology; 2024; 240(1):156-163. PubMed ID: 37952520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TIGIT: An emerging immune checkpoint target for immunotherapy in autoimmune disease and cancer.
    Zhao J; Li L; Yin H; Feng X; Lu Q
    Int Immunopharmacol; 2023 Jul; 120():110358. PubMed ID: 37262959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcriptome Profiling Identifies TIGIT as a Marker of T-Cell Exhaustion in Liver Cancer.
    Ostroumov D; Duong S; Wingerath J; Woller N; Manns MP; Timrott K; Kleine M; Ramackers W; Roessler S; Nahnsen S; Czemmel S; Dittrich-Breiholz O; Eggert T; Kühnel F; Wirth TC
    Hepatology; 2021 Apr; 73(4):1399-1418. PubMed ID: 32716559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.